Exodus Point Capital Management, LP Humanigen, Inc Call Options Transaction History

Exodus Point Capital Management, LP

  • $16.4 Billion
  • Q3 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2020

Feb 16, 2021
BUY
$7.97 - $21.66 $247,867 - $673,626
31,100 New
31,100 $545,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email